Patents for A61P 35 - Antineoplastic agents (221,099)
07/2007
07/25/2007CN101002764A Antineoplastic chemotherapy medicine composition, and its application
07/25/2007CN101002761A Stable injection docetaxel
07/25/2007CN101002757A Microemulsion of hypocrellin, and its preparing method
07/25/2007CN101002735A Recombination interleukin-2 frozen-dried preparation, and its preparing method
07/25/2007CN101002733A Stable elaioplast composition
07/25/2007CN101002730A Compounding anticarcinogen containing neovascular-inhibitor
07/25/2007CN101002729A Slow released anticarcinogen containing vasoinhibitor
07/25/2007CN101002728A Preparation of paclitaxel, and its preparing method
07/24/2007US7247738 Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids
07/24/2007US7247734 In which the 3-phenyl group is 2,4-dihydroxy-substituted, e.g., 4-[5-bromo-4-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-6-chloro-benzene-1,3-diol; heat shock protein 90 inhibitors
07/24/2007US7247717 Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
07/24/2007US7247716 Recombinant sequence, its preparation and use
07/24/2007US7247712 Complex of hepatitis B virus-specific antigenic peptides associated with heat shock proteins and the application thereof
07/24/2007US7247641 Compounds, derivatives, compositions, preparation and uses
07/24/2007US7247630 Nitrogen compounds such as 3-(5-hydroxyhexyl)-1-methyl-1H-imidazo(2,1-f)purine-2,4(3H,6H)-dione, used for prophylaxis of diseases associated with cytokine intracellular signal transduction
07/24/2007US7247629 Antitumoral analogs of et-743
07/24/2007US7247627 non-hygroscopic, crystalline anhydrous maleate salt of 5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
07/24/2007US7247624 e.g. 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole or salts for treating colon cancer
07/24/2007US7247618 Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
07/24/2007US7247615 Nucleic acid encoding peptides which antagonist epitope against prostate specific antigen; anticancer agents
07/24/2007US7247610 Suppression tumor growth
07/24/2007US7247477 For use in tissue engineering, research, diagnostics
07/24/2007US7247445 2-O sulfatase compositions and methods of hydrolyzing therewith
07/24/2007US7247444 Use of interleukin-19 to treat cervical cancer
07/24/2007US7247310 Combination of a microparticle of a fragment of solidified, chemically fixed tumor tissues or cells, sized so to allow phagocytosis of the fragment; and a cytokine and/or a cytokine-inducing agent such as a granulocyte-macrophage-colony stimulating factor and/or interleukin-2
07/24/2007US7247301 Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
07/24/2007CA2479846C Phosphonomethoxymethylpurine/pyrimidine derivatives
07/24/2007CA2246429C Erbb3 antibodies
07/24/2007CA2238274C Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids having retinoid-like biological activity
07/24/2007CA1341536C Transforming growth factor peptides
07/24/2007CA1341535C Transforming growth factor peptides
07/19/2007WO2007082208A2 Lanthionine-related compounds for the treatment of inflammatory diseases
07/19/2007WO2007082104A2 Compounds and methods for the treatment of cancer
07/19/2007WO2007081332A1 Cystine-knot fold cytokine
07/19/2007WO2007081235A1 Method for treating oncological diseases
07/19/2007WO2007081091A1 Rhodandse derivarives, a process for the preparation thereof and pharmaceutical composition containing the same
07/19/2007WO2007081031A1 Glycosyltransferase inhibitor
07/19/2007WO2007080277A1 Method for preparing antibodies selective for activating fc receptors
07/19/2007WO2007080124A1 Combination of mtor inhibitor and antipolate compound
07/19/2007WO2007080114A2 Macromolecule conjugate
07/19/2007WO2007080108A1 Composition ascorbic acid and a metal ion for selective killing of pathological mammalian cells
07/19/2007WO2007079982A1 (2 , 4 , 9-triaza-1 (2 , 4 ) -pyrimidina-3 ( 1 , 3 ) -benzenacyclononaphane-3 4-yl) -sulfoximine derivatives as selective aurora kinase inhibitors for the treatment of cancer
07/19/2007WO2007079826A1 Diazepinones
07/19/2007WO2007079820A1 Triazole derivatives
07/19/2007WO2007079666A1 Taxol derivatives with antitumor activity
07/19/2007WO2007059613B1 Antineoplastic compounds
07/19/2007WO2007059356A3 Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
07/19/2007WO2007058873A3 Imidazopyrazines as cyclin depentend kinase inhibitors
07/19/2007WO2007030668A3 Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
07/19/2007WO2007015174A3 Exosome-specific ligands, their preparartion and uses
07/19/2007WO2007007207A3 Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
07/19/2007WO2006113703A8 Carboline derivatives useful in the treatment of cancer
07/19/2007WO2006078783A3 Htm4 used for cell-cycle regulation through its interaction with kap
07/19/2007WO2006037623A3 New nuclear transcription factors regulators
07/19/2007WO2003035847A3 Il-13 mutein proteins, antibodies, compositions, methods and uses
07/19/2007US20070167644 Bifunctional energy-reversible acyl-compositions
07/19/2007US20070167630 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,13-dihydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-6,11-diene; antitumor compounds; using low toxic and inexpensive materials; product is readily purified; industrial production
07/19/2007US20070167611 Peptides and Peptidomimetics with Structural Similarity to Human p53 that Activate p53 Function
07/19/2007US20070167519 Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof
07/19/2007US20070167503 Substituted benzoxazoles as estrogenic agents
07/19/2007US20070167501 Bicyclo derivative
07/19/2007US20070167493 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof
07/19/2007US20070167481 Imidazonaphthyridines
07/19/2007US20070167461 USE OF SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES AS THERAPEUTIC AGENTS
07/19/2007US20070167459 Nitrogen-containing heterocyclic compounds and medicinal use thereof
07/19/2007US20070167445 Androgen receptor modulator compounds and methods
07/19/2007US20070167441 Xanthones, thioxanthones and acridinones as dna-pk inhibitors
07/19/2007US20070167377 Inhibitors of glycinamide ribonucleotide transformylase
07/19/2007US20070167365 Compositions and methods for modulating blood-brain barrier transport
07/19/2007US20070166796 Il-21 antagonists
07/19/2007US20070166753 Gene detection assay for improving the likelihood of an effective response to a her2 antibody cancer therapy
07/19/2007US20070166410 Follicle-stimulating hormone releasing agent
07/19/2007US20070166404 Composition and method for supporting cancer treatments
07/19/2007US20070166374 Orally administering edible oil homogenized with an edible wax and stigmasterol, campesterol, beta -sitosterol, chalinosterol, clionasterol, brassicasterol, alpha -spinasterol, daucosterol, desmosterol, and/or poriferasterol; repairing and promoting regeneration of mucosa in gastrointestinal tract
07/19/2007US20070166314 EpA2 monoclonal antibodies and methods of use thereof
07/19/2007US20070166312 Antibody against tumor specific antigen as target
07/19/2007US20070166296 Therapeutic Systems
07/19/2007US20070166286 Self-rearranging DNA vectors
07/19/2007US20070166284 Therapeutic regimen for treating cancer
07/19/2007US20070166280 Chemokines as adjuvants of immune response
07/19/2007DE102006002509A1 Verfahren zur Herstellung von Dimethylaminoarglabin-Hydrochlorid A process for preparing Dimethylaminoarglabin hydrochloride
07/19/2007CA2657683A1 Cystine-knot fold cytokine
07/19/2007CA2637069A1 Combination of mtor inhibitor and antipolate compound
07/19/2007CA2636793A1 Compounds and methods for the treatment of cancer
07/19/2007CA2636742A1 Ligands that have binding specificity for vegf and/or egfr and methods of use therefor
07/19/2007CA2636533A1 Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer
07/19/2007CA2636211A1 Taxol derivatives with antitumor activity
07/19/2007CA2636042A1 Lanthionine-related compounds for the treatment of inflammatory diseases
07/19/2007CA2634555A1 Diazepinones
07/19/2007CA2634553A1 Triazole derivatives
07/19/2007CA2633080A1 Method for preparing antibodies selective for activating fc receptors
07/19/2007CA2628186A1 Pyridopyrazine derivatives and the use thereof as medicaments in p13k related diseases
07/18/2007EP1808484A1 Nuclear transfer with differentiated fetal and adult donor cells
07/18/2007EP1808200A2 Cancer immuno-therapy
07/18/2007EP1808180A2 Modified GP 100 and uses thereof
07/18/2007EP1808178A1 Composition comprising Astragalus radix extracts for treating prostate cancer
07/18/2007EP1808175A1 Drugs, food or drink for improving pancreatic functions
07/18/2007EP1808172A2 Botanical extract compositions and methods of use
07/18/2007EP1807440A2 Novobiocin analogues as anticancer agents
07/18/2007EP1807438A1 Beta-glucuronidase cleavable prodrugs of o6-alkylguanine-dna alkyltransferase inactivators